A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1)
Completed · Phase 3 · NCT06687967
Conditions: Lichen Simplex Chronicus
At a glance
- Research payments reported, 2025
- $361,856
- U.S. investigators named
- 13
- Sites paid
- 14
- Planned or actual enrollment
- 142
About the trial
- Sponsor
- Sanofi (with Regeneron Pharmaceuticals)
- Tested
- Dupilumab (drug), Placebo (drug)
- Dates
- Started 2024-11-28; completion 2026-08-31
- Results posted
- Not yet
This is a parallel, Phase 3, 2-arm study for treatment. The purpose of this study is to measure improvement in pruritus with dupilumab subcutaneous injections compared with placebo injections in male and female participants aged at least 18 years with LSC. Study details include: The study duration will be up to 40 weeks. The treatment duration will be up to 24 weeks. The follow-up duration after treatment will be 12 weeks. The number of visits will be 6.
From ClinicalTrials.gov, last updated 2026-09-11. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $361,856 in research payments for this study in 2025 (40 payments).
Products named: Dupixent
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Howard L. Sofen, M.D. Dermatology · Los Angeles, CA
- Alejandro Pedrozo III, MD Dermatology · Miami, FL
- Michael P. Sheehan, M.D. Dermatology · Columbus, IN
- Wendy L. Mcfalda, D.O. Dermatology · Clarkston, MI
- Rita O. Pichardo, MD Dermatopathology · Winston Salem, NC
- Nicole M. Seminara, M.D. Dermatology · Huntersville, NC
- Michael Blankinship Dermatology · Fargo, ND
- James Del Rosso, DO Mohs Surgery · Las Vegas, NV
- Michael C. Cameron Dermatology · New York, NY
- Christina L. Feser, D.O. Dermatology · Clarksville, TN
- Asra Ali, M.D. Dermatology · Houston, TX
- Stephen K. Tyring, MD PHD Dermatology · Webster, TX
- David W. Bray, M.D. Dermatology · Alexandria, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Equity Medical Llc $149,224
- Care Access Research Llc $38,286
- Dermatology Research Associates $34,376
- Medcare Pharma Llc $26,100
- Onsite Clinical Solutions LLC $18,500
- Red River Research PArtners Llc $17,200
- International Clinical Research Tennessee Llc $15,700
- Wake Forest University Health Scien $15,500
- Medinext Research Network Llc $10,000
- Center for Clinical Studies Ltd LLP $9,570
- Michigan Center for Research Compan $9,500
- Jdr Dermatology Research Llc $7,400
- Wake Forest University Health Science $6,873
- Southern Clinical Research Center $3,627
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.